Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

58
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58
Hepatitis01:25

Hepatitis

86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

25
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

563
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
563
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a public health and prevention-oriented approach to stimulant-induced psychosis.

Addiction (Abingdon, England)·2026
Same author

A call for action: Closing the evidence gap in management of stimulant-induced psychosis.

Addiction (Abingdon, England)·2026
Same author

COmprehensive Meta-analysis and meta-regression of Psychiatric disorders in people with Amphetamine-type Stimulant use disorder Study (COMPASS): a protocol for a pilot study, a systematic review and a meta-analysis series.

Systematic reviews·2026
Same author

Combined exercise and Hawthorn protect against learning impairments and hippocampal damage from trimethyltin neurotoxicity in rat.

Scientific reports·2025
Same author

Use of herbal medicine related to anxiety and depression in the general population of southeast Iran during the COVID-19 pandemic.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2025
Same author

The effect of wet cupping on reactive airway dysfunction syndrome (RADS) caused by early exposure to chlorine gas: A randomized clinical trial.

Avicenna journal of phytomedicine·2025

Related Experiment Video

Updated: May 1, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K

Interferon alpha-2b therapy in chronic hepatitis delta.

Maryam Keshvari1, Seyed Moayed Alavian2, Heidar Sharafi2

  • 1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran ; Middle East Liver Disease (MELD) Center, Tehran, IR Iran.

Hepatitis Monthly
|April 19, 2014
PubMed
Summary

Hepatitis B and D virus (HBV/HDV) coinfection shows a low response rate to interferon alpha-2b (IFN α-2b) therapy. Most patients did not achieve sustained virological response or relapsed after treatment.

Keywords:
Hepatitis DInterferon-alphaIran

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.6K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.1K

Related Experiment Videos

Last Updated: May 1, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.6K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.1K

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis B virus (HBV) and hepatitis D virus (HDV) coinfection affects 5% of HBV carriers.
  • HBV/HDV coinfection is a leading cause of cirrhosis and end-stage liver disease.
  • Interferon alpha (IFN α) is the sole approved therapy for chronic hepatitis D, but response rates are low.

Purpose of the Study:

  • To evaluate the efficacy of interferon alpha-2b (IFN α-2b) in treating patients with HBV/HDV coinfection.

Main Methods:

  • A cross-sectional study involved 20 HBsAg carriers positive for Anti-HDVAb and HDV RNA.
  • Patients received IFN α-2b at 5 million units (MU) three times weekly for three years or daily for one year.
  • Sustained virological response (SVR) was defined as undetectable HDV RNA 6 months post-treatment.

Main Results:

  • Only 15% (3/20) of patients achieved SVR.
  • 50% (10/20) experienced relapse after treatment cessation.
  • 35% (7/20) did not achieve HDV clearance during therapy.

Conclusions:

  • High-dose, long-duration IFN α-2b therapy demonstrates a very low response rate in HBV/HDV coinfected patients.
  • Current IFN α-based treatments are largely ineffective for sustained viral clearance in this population.